Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: A laser Doppler flowmetry study in rats: Laboratory investigation

Journal of Neurosurgery

Volumn 109, Issue 6, 2008, Pages 1134-1140

  Schubert, Gerrit A ^a   Schilling, Lothar ^a   Thomé, Claudius ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Endothelin; Endothelin A receptor antagonist; Laser Doppler flowmetry; Rat; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

CLAZOSENTAN; ENDOTHELIN; DIOXANE DERIVATIVE; ENDOTHELIN RECEPTOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRAIN VASOSPASM; CISTERNA MAGNA; CONTROLLED STUDY; INTRACRANIAL PRESSURE; LASER DOPPLER FLOWMETRY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ONLINE ANALYSIS; PERFUSION PRESSURE; PRIORITY JOURNAL; RAT; SUBARACHNOID HEMORRHAGE; ANIMAL; BLOOD FLOW; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; DIOXANES; ENDOTHELINS; LASER-DOPPLER FLOWMETRY; MALE; MODELS, ANIMAL; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; TIME FACTORS; VASOCONSTRICTION; VASOSPASM, INTRACRANIAL;

EID: 58149391007     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/JNS.2008.109.12.1134     Document Type: Article

References (62)

1. Baldwin ME, Macdonald RL, Huo D, Novakovia RL, Goldenberg FD, Frank JI, et al: Early vasospasm on admission angiography in patients with aneurysmal subarachnoid hemorrhage is a predictor for in-hospital complications and poor outcome. Stroke 35:2506-2511, 2004 (Pubitemid 39458408)
2. Battistini B, D'Orleans-Juste P, Sirois P: Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 68:600-628, 1993 (Pubitemid 23202790)
3. Bavbek M, Polin R, Kwan AL, Arthur AS, Kassell NF, Lee KS: Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke 29:1930-1936, 1998 (Pubitemid 28399993)
4. Bederson JB, Germano IM, Guarino L: Cortical blood flow and cerebral perfusion pressure in a new noncraniotomy model of subarachnoid hemorrhage in the rat. Stroke 26:1086-1092, 1995
5. Bederson JB, Levy AL, Ding WH, Kahn R, DiPerna CA, Jenkins AL III, et al: Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery 42:352-1352, 1998 (Pubitemid 28076796)
6. Bhardwaj A, Wu Y, Hurn PD, Kirsch JR, Traystman RJ: Administration of selective endothelin receptor type A antagonist Ro 61-1790 does not improve outcome in focal cerebral ischemia in cat. J Cereb Blood Flow Metab 20:499-504, 2000 (Pubitemid 30164894)
7. Clozel M, Watanabe H: BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 52:825-834, 1993 (Pubitemid 23045965)
8. Cocks TM, Malta E, King SJ, Woods RL, Angus JA: Oxyhaemoglobin increases the production of endothelin-1 by en dothelial cells in culture. Eur J Pharmacol 196:177-182, 1991
9. Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneller T, Ley KF, et al: Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 53:123-125, 2003 (Pubitemid 36801515)
10. Dumont AS, Kassell NF: Vasospasm. J Neurosurg 103:1-3, 2005
11. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, et al: Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172:1741-1748, 1990
12. Faraci FM, Heistad DD: Regulation of the cerebral circulation: role of endothelium and potassium channels Physiol Rev 78:53-97, 1998
13. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schutt S, et al: Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke 31:2971-2975, 2000
14. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schutt S, et al: Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 70:534-537, 2001 (Pubitemid 32269696)
15. Foley PL, Caner HH, Kassell NF, Lee KS: Reversal of sub arach noid hemorrhage-induced vasoconstriction with an en do thelin receptor antagonist. Neurosurgery 34:108-113, 1994
16. Jakobsen M: Role of initial brain ischemia in subarachnoid hemorrhage following aneurysm rupture. A pathophysiological survey. Acta Neurol Scand Suppl 141:1-33, 1992
17. Josko J, Hendryk S, Jedrzejowska-Szypula H, Gwozdz B, Herman ZS, Gawlik R: Influence endothelin ETA receptor antagonist-BQ-123-on changes of endothelin-1 level in plasma of rats with acute vasospasm following subarachnoid hemorrhage. J Physiol Pharmacol 49:367-375, 1998 (Pubitemid 28461974)
18. Juvela S: Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 92:390-400, 2000
19. Kasuya H, Weir BK, White DM, Stefansson K: Mechanism of oxyhemoglobin-induced release of endothelin-1 from cultured vascular endothelial cells and smooth-muscle cells. J Neu rosurg 79:892-898, 1993 (Pubitemid 23342454)
20. Kim JM, Bak KH, Kim CH, Park IK, Oh SJ, Choi HK: The role of endothelin-1 as predictor of the symptomatic vasospasm in acute stage of subarachnoid haemorrhage. Acta Neu rochir Suppl 77:77-79, 2001
21. Kirchengast M, Luz M: Endothelin receptor antagonists: clinical realities and future directions. J Cardiovasc Pharmacol 45:182-191, 2005 (Pubitemid 40170682)
22. Kwan AL, Lin CL, Chang CZ, Wu HJ, Hwong SL, Jeng AY, et al: Continuous intravenous infusion of CGS 26303, an endothelin-converting enzyme inhibitor, prevents and reverses cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 49:422-429, 2001
23. Levin ER: Endothelins. N Engl J Med 333:356-363, 1995
24. Macdonald RL: Pathophysiology and molecular genetics of va sospasm. Acta Neurochir Suppl 77:7-11, 2001
25. Masaki T: The endothelin family: an overview. J Cardiovasc Pharmacol 35:S3-S5, 2000
26. Masaki T, Vane JR, Vanhoutte PM: International Union of Phar macology nomenclature of endothelin receptors. Pharmacol Rev 46:137-142, 1994 (Pubitemid 24185148)
27. Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K: Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 2:1402, 1989 (Pubitemid 20003021)
28. Nagai H, Noda S, Mabe H: Experimental cerebral vasospasm. Part 2: effects of vasoactive drugs and sympathectomy on ear ly and late spasm. J Neurosurg 42:420-428, 1975
29. Nagai H, Suzuki Y, Sugiura M, Noda S, Mabe H: Experimental cerebral vasospasm. 1: Factors contributing to early spasm. J Neurosurg 41:285-292, 1974
30. Nishizawa S, Chen D, Yokoyama T, Yokota N, Otha S: Endothelin-1 initiates the development of vasospasm after subarachnoid haemorrhage through protein kinase C activation, but does not contribute to prolonged vasospasm. Acta Neuro chir (Wien) 142:1409-1415, 2000 (Pubitemid 32204515)
31. Ohlstein EH, Storer BL: Oxyhemoglobin stimulation of endothelin production in cultured endothelial cells. J Neurosurg 77:274-278, 1992
32. Patel TR, Galbraith S, McAuley MA, McCulloch J: Endothelin-mediated vascular tone following focal cerebral ischaemia in the cat. J Cereb Blood Flow Metab 16:679-687, 1996 (Pubitemid 26227078)
33. Patel TR, McAuley MA, McCulloch J: Effects on feline pial arterioles in situ of bosentan, a non-peptide endothelin receptor antagonist. Eur J Pharmacol 260:65-71, 1994
34. Pluta RM, Boock RJ, Afshar JK, Clouse K, Bacic M, Ehrenreich H, et al: Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 87:287-293, 1997 (Pubitemid 27349116)
35. Proust F, Hannequin D, Langlois O, Freger P, Creissard P: Causes of morbidity and mortality after ruptured aneurysm surgery in a series of 230 patients. The importance of control angiography. Stroke 26:1553-1557, 1995
36. Qureshi AI, Sung GY, Suri MA, Straw RN, Guterman LR, Hopkins LN: Prognostic value and determinants of ultraearly angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 44:967-974, 1999
37. Rosenstein J, Suzuki M, Symon L, Redmond S: Clinical use of a portable bedside cerebral blood flow machine in the management of aneurysmal subarachnoid hemorrhage. Neurosurgery 15:519-525, 1984 (Pubitemid 14022011)
38. Roux S, Breu V, Ertel SI, Clozel M: Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 77:364-376, 1999 (Pubitemid 29207019)
39. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al: Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283:1110-1118, 1997 (Pubitemid 28016483)
40. Roux S, Löffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP: The role of endothelin in experimental cerebral vasospasm. Neurosurgery 37:78-86, 1995
41. Sakurai T, Yanagisawa M, Masaki T: Molecular characterization of endothelin receptors. Trends Pharmacol Sci 13:103-108, 1992
42. Sehba FA, Ding WH, Chereshnev I, Bederson JB: Effects of S-nitrosoglutathione on acute vasoconstriction and glutamate release after subarachnoid hemorrhage. Stroke 30:1955-1961, 1999 (Pubitemid 29411841)
43. Sehba FA, Mostafa G, Knopman J, Friedrich V, Bederson JB: Acute alterations in microvascular basal lamina after subarachnoid hemorrhage. J Neurosurg 101:633-640, 2004 (Pubitemid 43186422)
44. Sehba FA, Schwartz AY, Chereshnev I, Bederson JB: Acute decrease in cerebral nitric oxide levels after subarachnoid hem orrhage. J Cereb Blood Flow Metab 20:604-611, 2000 (Pubitemid 30164904)
45. Sercombe R, Dinh YR, Gomis P: Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol 88:227-249, 2002 (Pubitemid 34302973)
46. Sessler DI: Mild perioperative hypothermia. N Engl J Med 336:1730-1737, 1997
47. Shigeno T, Clozel M, Sakai S, Saito A, Goto K: The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 37:87-91, 1995
48. Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T: Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 53:131-135, 2000 (Pubitemid 30122318)
49. Suzuki M, Ogawa A, Sakurai Y, Nishino A, Venohara K, Mizoi K, et al: Thrombin activity in cerebrospinal fluid after sub arachnoid hemorrhage. Stroke 23:1181-1182, 1992
50. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K: The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 77:96-100, 1992
51. Thomé C, Schubert GA, Piepgras A, Elste V, Schilling L, Schmiedek P: Hypothermia reduces acute vasospasm following SAH in rats. Acta Neurochir Suppl 77:255-258, 2001 (Pubitemid 33759260)
52. Thomé C, Schubert GA, Schilling L: Hypothermia as a neuroprotective strategy in subarachnoid hemorrhage: a pathophysiological review focusing on the acute phase. Neurol Res 3:229-237, 2005 (Pubitemid 40523794)
53. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ: Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneursymal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 36:1627-1632, 2005 (Pubitemid 41098752)
54. Tsurutani H, Ohkuma H, Suzuki S: Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. Stroke 34:1497-1500, 2003 (Pubitemid 36693524)
55. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thomé C, Ringel F, et al: Clazosentan (ASV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9-17, 2005 (Pubitemid 43193928)
56. Wanebo JE, Arthur AS, Louis HG, West K, Kassell NF, Lee KS, et al: Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm. Neurosurgery 43:1409-1418, 1998 (Pubitemid 28545872)
57. Weir B: The pathophysiology of cerebral vasospasm. Br J Neu rosurg 9:375-390, 1995
58. Weir B, Grace M, Hansen J, Rothberg C: Time course of vasospasm in man. J Neurosurg 48:173-178, 1978 (Pubitemid 8269962)
59. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1988 (Pubitemid 19005277)
60. Zimmermann M, Seifert V: Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 43:863-866, 1998 (Pubitemid 28436337)
61. Zimmermann M, Seifert V: Prevention of cerebral vasospasms after experimental subarachnoid hemorrhage by the endothelin receptor antagonist RO 47-0203. Zentralbl Neurochir 57:143-149, 1996 (Pubitemid 26265449)
62. Zuccarello M: Endothelin: the "prime suspect" in cerebral vasospasm. Acta Neurochir Suppl 77:61-65, 2001